(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer (TEST)
(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer (TEST)
An interactive patient case video series from breast cancer specialists
An interactive patient case video series from breast cancer specialists
Prof Valentina Guarneri
In this first interactive patient case video from BREAST CANCER CONNECT expert Dr Elisa Agostinetto, you will explore the complexities of a patient facing ER+/HER2- de novo metastatic breast cancer.
As you journey through the entire diagnostic and treatment process, you'll interact and engage with valuable information, challenging questions and clickable resources along the way.
Video 2 Coming Soon: Prof. Valentina Guarneri presents a patient with ER+/HER2- metastatic breast cancer in a second interactive patient case video coming soon.
Prof Valentina Guarneri
Medical Oncology
University of Padova
Italy
ER+HER2 - De Novo Metastatic Breast Cancer
Interactive patient case | 
28 min
|
Sep 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Clinical Takeaways
-
Assessing tumour characteristics, including prevalent mutations like ESR1 and PIK3CA, can significantly influence and guide treatment choices in patients with ER+/HER2- metastatic breast cancer
-
Liquid biopsy, specifically blood-based ctDNA analysis, is the preferred method for detecting ESR1 mutations due to its heightened sensitivity and the avoidance of repeat biopsies at metastatic sites
-
Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2- metastatic breast cancer harbouring an ESR1 mutation
-
Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice
This programme is endorsed by 
This educational programme is supported by an Independent Medical Education Grant from (TEST) Menarini Stemline Oncology
Other programmes of interest
11 min
